Los Angeles, June 1, 2022 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announces that an independent safety review committee has unanimously recommended further trial advancement following review of the favorable results from the company’s Phase 1a dose […]
Los Angeles, May 19, 2022 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announces a forthcoming presentation by scientific founder Dr. Caius Radu at the Los Angeles Bioscience Ecosystem Summit 2022 (“LABEST”). Presentation Details: Title: Development of a […]
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00Tretherahttps://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngTrethera2022-05-19 22:14:542022-05-19 23:39:49Trethera Scientific Founder Dr. Caius Radu To Present Research At Los Angeles Bioscience Ecosystem Summit 2022
Los Angeles, May 11, 2022 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announces the completion of a follow-on seed financing of $3.8 million from its existing investors. Funds will be used for working capital purposes. “This capital […]
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00Tretherahttps://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngTrethera2022-05-13 00:43:202022-05-13 00:44:58Trethera Announces Completion of $3.8 Million Seed Funding Round From Current Investors
Los Angeles, March 22, 2022 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced an upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting. Dr. Caius Radu, of the University of California Los Angeles, […]
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png00Tretherahttps://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.pngTrethera2022-03-22 19:54:032022-03-23 14:40:48Trethera Announces Prostate Cancer Poster Presentation at the American Association for Cancer Research Annual Meeting
Los Angeles, December 9, 2021— Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced that the first patient cohort completed their full dose cycle with no serious adverse events (SAEs) in its multi-site Phase 1 oncology trial. The safety and tolerability of TRE-515, a first-in-class drug targeting the enzyme deoxycytidine kinase (dCK) […]
Trethera Phase 1 Solid Tumors Trial Dose Escalates To Fourth Cohort After Safety Review Committee Determines Primary Trial Endpoint Achieved
/in News /by TretheraLos Angeles, June 1, 2022 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announces that an independent safety review committee has unanimously recommended further trial advancement following review of the favorable results from the company’s Phase 1a dose […]
Trethera Scientific Founder Dr. Caius Radu To Present Research At Los Angeles Bioscience Ecosystem Summit 2022
/in News /by TretheraLos Angeles, May 19, 2022 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announces a forthcoming presentation by scientific founder Dr. Caius Radu at the Los Angeles Bioscience Ecosystem Summit 2022 (“LABEST”). Presentation Details: Title: Development of a […]
Trethera Announces Completion of $3.8 Million Seed Funding Round From Current Investors
/in News /by TretheraLos Angeles, May 11, 2022 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announces the completion of a follow-on seed financing of $3.8 million from its existing investors. Funds will be used for working capital purposes. “This capital […]
Trethera Announces Prostate Cancer Poster Presentation at the American Association for Cancer Research Annual Meeting
/in News /by TretheraLos Angeles, March 22, 2022 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced an upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting. Dr. Caius Radu, of the University of California Los Angeles, […]
Safety Review Committee Advances Trethera Phase 1 Solid Tumors Trial to Next Dose After First Patient Cohort Achieves Primary Endpoint
/in News /by TretheraLos Angeles, December 9, 2021— Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced that the first patient cohort completed their full dose cycle with no serious adverse events (SAEs) in its multi-site Phase 1 oncology trial. The safety and tolerability of TRE-515, a first-in-class drug targeting the enzyme deoxycytidine kinase (dCK) […]